Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/26/03	ILA 270.50	+1.39%	6,258
02/26/02	ILA 266.80	-2.09%	49,297
01/26/01	ILA 272.50	-0.22%	4,539
30/26/30	ILA 273.10	-1.90%	45,210
29/26/29	ILA 278.40	-2.28%	12,071

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 04:14:07 03/07/2026 pm IST			5-day change	1st Jan Change
270.50 ^ILa	+1.39%		-5.05%	-50.90%

22/06	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
17/06	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI

Market Cap	7.91Cr 791.07Cr 2.64Cr 2.31Cr 2.12Cr 1.98Cr 3.75Cr 251.43Cr 3.81Cr 25Cr 9.9Cr 123.48Cr 9.92Cr 9.7Cr 426.1Cr	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	5.9Cr 589.67Cr 1.97Cr 1.72Cr 1.58Cr 1.47Cr 2.79Cr 187.42Cr 2.84Cr 19Cr 7.38Cr 92Cr 7.39Cr 7.23Cr 317.62Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

22/06	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
17/06	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
30/03	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
25/03	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
24/03	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
24/03	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
04/03	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03/03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03/03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
27/02	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
03/25/03	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/25/11	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI

23/06	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03/03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
02/03	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
27/02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR
26/02	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation	PR

Matricelf Ltd Share Price

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news : Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.39%
1 week	-5.05%
Current month	-0.95%
1 month	-2.13%
3 months	-20.37%
6 months	-52.96%
Current year	-50.90%

1 week	260	289.8
1 month	248	326
Current year	212	853
1 year	204	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Manager	Title	Age	Since
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	01/06/2019
Asaf Toker CEO	Chief Executive Officer	53	01/06/2019
Alon Sinai COO	Chief Operating Officer	58	01/07/2019

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	58	01/07/2019
Tal Dvir BRD	Director/Board Member	51	01/06/2019
Stanley Hirsch BRD	Director/Board Member	68	27/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+1.39%	-5.05%	+17.00%	-38.35%	2.64Cr
LONZA GROUP AG	+1.70%	+7.41%	+3.12%	+8.46%	4.99TCr
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+605.33%	4.02TCr
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.35%	3.46TCr
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+64.58%	3.31TCr
CELLTRION, INC.	+3.96%	+10.67%	+11.89%	+38.86%	2.75TCr
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	1.7TCr
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+133.27%	1.59TCr
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+13.67%	+19.09%	1.39TCr
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+99.12%	1.35TCr
Average	+2.09%	+4.74%	+72.93%	+102.67%	2.46TCr
Weighted average by Cap.	+2.07%	+6.53%	+90.74%	+137.72%

	2024	2025
Net sales	-	-
Net income	-1.56Cr -155.82Cr -52.02L -45.5L -41.76L -38.91L -73.78L -50Cr -74.96L -5.02Cr -1.95Cr -24Cr -1.95Cr -1.91Cr -84Cr	-2.78Cr -278.21Cr -92.88L -81.23L -74.56L -69.48L -1.32Cr -88Cr -1.34Cr -8.96Cr -3.48Cr -43Cr -3.49Cr -3.41Cr -149.85Cr
Net Debt	-1.07Cr -106.8Cr -35.66L -31.18L -28.62L -26.67L -50.57L -34Cr -51.38L -3.44Cr -1.34Cr -17Cr -1.34Cr -1.31Cr -58Cr	-2.01Cr -201.4Cr -67.24L -58.81L -53.97L -50.29L -95.36L -64Cr -96.89L -6.48Cr -2.52Cr -31Cr -2.52Cr -2.47Cr -108.48Cr